Inhibikase Therapeutics, Inc. (IKT)
USD 2.25
(0.45%)
USD 2.25
(0.45%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 260.5 Thousand | 123.44 Thousand | 3.1 Million | 698.46 Thousand | 1.12 Million | 4.04 Million |
| Cost of Revenue | 13.61 Million | 6723.00 | 11.35 Million | 893.8 Thousand | 2.55 Million | 3.64 Million |
| Gross Profit | -13.35 Million | 116.71 Thousand | -8.25 Million | -195.33 Thousand | -1.42 Million | 393.84 Thousand |
| Operating Expenses | 6.73 Million | 18.12 Million | 14.76 Million | 2.81 Million | 5.69 Million | 2.12 Million |
| Selling, General and Administrative Expenses | 6.73 Million | 6.21 Million | 6.5 Million | 2.62 Million | 4.26 Million | 2.51 Million |
| Research and Development Expenses | 13.61 Million | 12.03 Million | 11.35 Million | 893.8 Thousand | 2.55 Million | 3.64 Million |
| Other Expenses | -13.61 Million | -123.44 Thousand | -3.1 Million | -698.46 Thousand | -1.12 Million | - |
| Cost and Expenses | 20.35 Million | 18.12 Million | 14.76 Million | 2.81 Million | 5.69 Million | 2.12 Million |
| Operating Income | -20.08 Million | -18.12 Million | -14.76 Million | -2.81 Million | -5.69 Million | -2.12 Million |
| Interest Expense | - | 74.45 Thousand | 19.92 Thousand | 29.4 Thousand | 24.83 Thousand | 30.33 Thousand |
| Income Tax Expense | - | -148.9 Thousand | 19.92 Thousand | 29.4 Thousand | 24.83 Thousand | -161.14 Thousand |
| Earnings before Tax | -19.02 Million | -18.05 Million | -14.78 Million | -2.84 Million | -5.72 Million | -2.15 Million |
| Net Income | -19.02 Million | -17.9 Million | -14.8 Million | -2.87 Million | -5.74 Million | -2.15 Million |
| Earnings Per Share Basic | -3.57 | -4.26 | -4.88 | -1.72 | -3.34 | -1.61 |
| Earnings Per Share Diluted | -3.57 | -4.26 | -4.88 | -1.72 | -3.34 | -1.61 |
| Weighted Average Shares Outstanding | 5.33 Million | 4.2 Million | 3.03 Million | 1.67 Million | 1.72 Million | 1.33 Million |
| Weighted Average Shares Outstanding (Diluted) | 5.33 Million | 4.2 Million | 3.03 Million | 1.67 Million | 1.72 Million | 1.33 Million |
| Gross Margin | -51.28 | 0.95 | -2.66 | -0.28 | -1.27 | 0.10 |
| EBIT Margin | -76.44 | -146.81 | -4.76 | -4.04 | -5.08 | -0.53 |
| Profit Margin | -73.05 | -145.05 | -4.78 | -4.12 | -5.12 | -0.53 |
| EBITDA | -19.91 Million | -18.12 Million | -14.76 Million | -2.81 Million | -5.69 Million | - |
| Earnings Before Tax Margin | -77.12 | -146.86 | -4.76 | -4.04 | -5.08 | -0.53 |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | - | - | 1.00 | 260.5 Thousand | 79.56 Thousand | 116.41 Thousand |
| Cost of Revenue | 6569.00 | 6568.00 | 6568.00 | 177.39 Thousand | 6568.00 | 159.2 Thousand |
| Gross Profit | -6569.00 | -6568.00 | -6567.00 | 83.1 Thousand | 73 Thousand | -42.79 Thousand |
| Operating Expenses | 5.04 Million | 4.77 Million | 4.39 Million | 20.17 Million | 4.76 Million | 6.2 Million |
| Selling, General and Administrative Expenses | 1.96 Million | 2.02 Million | 1.39 Million | - | 1.62 Million | 1.78 Million |
| Research and Development Expenses | 3.07 Million | 2.75 Million | 3 Million | - | 3.22 Million | 4.53 Million |
| Other Expenses | -3.07 Million | - | 89.68 Thousand | - | - | - |
| Cost and Expenses | 5.05 Million | 4.78 Million | 4.4 Million | 20.35 Million | 4.76 Million | 6.2 Million |
| Operating Income | -5.05 Million | -4.78 Million | -4.4 Million | -20.08 Million | -4.76 Million | -6.2 Million |
| Interest Expense | - | - | -661.6 Thousand | - | - | 424.43 Thousand |
| Income Tax Expense | 1.00 | 2.00 | 1.00 | 2.00 | 46.16 Thousand | 37.11 Thousand |
| Earnings before Tax | -4.95 Million | -4.64 Million | -4.17 Million | -19.02 Million | -4.59 Million | -5.77 Million |
| Net Income | -4.95 Million | -4.64 Million | -4.17 Million | -19.02 Million | -4.59 Million | -5.77 Million |
| Earnings Per Share Basic | -0.66 | -0.73 | -0.68 | - | -0.86 | -1.11 |
| Earnings Per Share Diluted | -0.66 | -0.73 | -0.68 | - | -0.86 | -1.11 |
| Weighted Average Shares Outstanding | 7.53 Million | 6.34 Million | 6.18 Million | 5.33 Million | 5.34 Million | 5.22 Million |
| Weighted Average Shares Outstanding (Diluted) | 7.53 Million | 6.34 Million | 6.18 Million | 5.33 Million | 5.34 Million | 5.22 Million |
| Gross Margin | - | - | -6567.00 | 0.32 | 0.92 | -0.37 |
| EBIT Margin | - | - | -4.39 Million | - | -59.85 | -51.91 |
| Profit Margin | - | - | -4.17 Million | -73.05 | -57.75 | -49.63 |
| EBITDA | -5.04 Million | -4.77 Million | -4.39 Million | - | -4.76 Million | -6.04 Million |
| Earnings Before Tax Margin | - | - | -4.4 Million | -77.12 | -59.93 | -53.28 |
CDNTF
MANVF
002681
1897
DFS
300278